

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10596731
	Filing Date		2006-11-16
	First Named Inventor		Susanne Alenfalk
	Art Unit		1624
	Examiner Name		Mark L. Berch
	Attorney Docket Number		133087.10701 101340-1P US

U.S.PATENTS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5661145		1997-08-26	Davis	
	2	7235543		2007-06-26	Burnett et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20080064676		2008-03-13	AstraZeneca AB	
	2	20070142304		2007-06-21	AstraZeneca AB	
	3	20030119757		2003-06-26	Schering Corp.	
	4	20030119428		2003-06-26	Schering Corp.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10596731
	Filing Date	2006-11-16
	First Named Inventor	Susanne Alenfalk
	Art Unit	1624
	Examiner Name	Mark L. Berch
	Attorney Docket Number	133087.10701 101340-1P US

5	20040018060	2003-06-26	Schering Corp.	
6	20040018061	2004-01-29	Jansson	
7	20040254369	2004-12-16	Patel	
8	20050096307	2005-05-05	Schering Corp.	
9	20050267049	2005-12-01	Goulet et al.	
10	20060046996	2006-03-02	Nissan Chemical Ind Ltd.	
11	20060069080	2006-06-29	Incyte Corp.	
12	20070078098	2007-04-05	Merck and Co., Inc.	
13	20070129540	2007-06-07	Opus Organics Pvt Ltd.	
14	20070049748	2007-03-01	Dr. Reddys Lab Ltd	
15	20020137690	2002-09-26	Ghosai et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10596731	
		Filing Date		2006-11-16	
		First Named Inventor		Susanne Alenfalk	
		Art Unit		1624	
		Examiner Name		Mark L. Berch	
		Attorney Docket Number		133087.10701 101340-1P US	

	16	20070155675		2007-07-05	Burnett et al.	
	17	20070155674		2007-07-05	Burnett et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2005061452	WO		2005-07-07	AstraZeneca AB		<input type="checkbox"/>
	2	2005062824	WO		2005-07-14	Merck & Co. Inc.		<input type="checkbox"/>
	3	2006017257	WO		2006-02-16	Phenomix Corp.		<input type="checkbox"/>
	4	2005061451	WO		2005-07-07	AstraZeneca AB		<input type="checkbox"/>
	5	2005062897	WO		2005-07-14	Dr Reddys Lab Ltd		<input type="checkbox"/>
	6	2005066120	WO		2005-07-21	Ranbaxy Lab Ltd.		<input type="checkbox"/>
	7	2005069900	WO		2005-08-04	Merck & Co. Inc.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				Application Number		10596731		
				Filing Date		2006-11-16		
				First Named Inventor		Susanne Alenfalk		
				Art Unit			1624	
				Examiner Name		Mark L. Berch		
				Attorney Docket Number			133087.10701 101340-1P US	

	8	03026643	WO		2003-04-03	Schering Corp.		<input type="checkbox"/>
	9	04043456	WO		2004-05-27	Schering Corp.		<input type="checkbox"/>
	10	04043457	WO		2004-05-27	Schering Corp.		<input type="checkbox"/>
	11	2005113495	WO		2005-12-01	Aventis Pharma GMBH		<input type="checkbox"/>
	12	04099132	WO		2004-11-18	Ranbaxy Laboratories Limited		<input type="checkbox"/>
	13	04107958	WO		2004-12-16	Schering Corp.		<input type="checkbox"/>
	14	05000353	WO		2005-01-06	Kotobuki Pharmaceutical Co. Ltd.		<input type="checkbox"/>
	15	2005021495	WO		2005-03-10	Microbia Inc.		<input type="checkbox"/>
	16	2007075702	WO		2007-07-05	Schering Corporation		<input type="checkbox"/>
	17	2005033100	WO		2005-07-25	Lipideon Biotechnology AG		<input type="checkbox"/>
	18	05042692	WO		2005-05-12	Forbes Medi Tech Inc.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				Application Number		10596731
				Filing Date		2006-11-16
				First Named Inventor		Susanne Alenfalk
				Art Unit		1624
				Examiner Name		Mark L. Berch
				Attorney Docket Number		133087.10701 101340-1P US

	19	2005113496	WO		2005-12-01	Aventis Pharma GMBH		<input type="checkbox"/>
	20	2005044256	WO		2005-05-19	Merck & Co. Inc.		<input type="checkbox"/>
	21	2005049592	WO		2005-06-02	Hetero Drugs Ltd.		<input type="checkbox"/>
	22	2005047248	WO		2005-05-26	Microbia Inc.		<input type="checkbox"/>
	23	2005058316	WO		2005-06-30	Sumitomo Pharma		<input type="checkbox"/>
	24	1362855	EP		2003-11-19	Kotobuki Pharmaceutical Co. Ltd.		<input type="checkbox"/>
	25	1413331	EP		2001-09-21	Schering Corporation		<input type="checkbox"/>
	26	2007008529	WO		2007-01-18	Kalypsys, Inc.		<input type="checkbox"/>
	27	2007008541	WO		2007-01-18	Kalypsys, Inc.		<input type="checkbox"/>
	28	2007030721	WO		2007-03-15	Teva Pharmaceutical Industries Ltd. et al.		<input type="checkbox"/>
	29	2005067903	WO		2005-07-25	Panacea Boitec Ltd.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10596731	
		Filing Date		2006-11-16	
		First Named Inventor		Susanne Alenfalk	
		Art Unit		1624	
		Examiner Name		Mark L. Berch	
		Attorney Docket Number		133087.10701 101340-1P US	

	30	2004081002	WO		2004-09-23	Schering Corporation		<input type="checkbox"/>
--	----	------------	----	--	------------	----------------------	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Notice of allowance dated July 31, 2008 for Application No. 10/519,897. (133087.07001)	<input type="checkbox"/>
	2	Office Action dated February 28, 2008 for Application No. 10/519,897. (133087.07001)	<input type="checkbox"/>
	3	Notice of allowance dated August 28, 2007 for Application No. 10/519,897. (133087.07001)	<input type="checkbox"/>
	4	Office Action dated May 1, 2007 for Application No. 10/519,897. (133087.07001)	<input type="checkbox"/>
	5	Vaccaro et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors," Bioorganic & Medicinal Chemistry Letters (1998) 8:319-322.	<input type="checkbox"/>
	6	Clader et al., "2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the HeterocyclicNucleus," J. Med Chem (1996) 39:3684-3693.	<input type="checkbox"/>
	7	McKittrick et al., "Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorptioninhibitors, Bioorganic & Medicinal Chemistry Letters (1996) 6(16):1947-1950.	<input type="checkbox"/>
	8	Burnett et al., "2-Azetidinones as Inhibitors of Cholesterol Absorption," J. Med Chem (1994) 12:1733-1736.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10596731
	Filing Date		2006-11-16
	First Named Inventor		Susanne Alenfalk
	Art Unit		1624
	Examiner Name		Mark L. Berch
	Attorney Docket Number		133087.10701 101340-1P US

9	Castaner et al., "Ezetimibe Hypolipidemic, Cholesterol absorption inhibitor," Drugs of the Future (2000) 25(7):679-685.	<input type="checkbox"/>
10	Vaccaro et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: Enhanced potency by modification of the sugar," Bioorganic & Medicinal Chemistry Letters (1998) 8:313-318.	<input type="checkbox"/>
11	Fu et al., "Process for preparing Ezetimibe intermediate by an acid enhanced chemo- and enantioselective CBS-catalyzed ketone reduction," Tetrahedron Letters (2003) 44:801-804.	<input type="checkbox"/>
12	Kirkup et al., "(i)-SCH 57939: synthesis and pharmacological properties of a potent, metabolically stable cholesterolabsorption inhibitor," Bioorganic & Medicinal Chemistry Letters (1996) 6(17):2069-2072.	<input type="checkbox"/>
13	Rosenblum et al., "Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.," J. Med Chem (1998) 41:973-980.	<input type="checkbox"/>
14	Wu et al., "A Novel One-Step Diastereo- and Enantioselective Formation of trans-Azetidinones and Its Application to the Total Synthesis of Cholesterol Absorption Inhibitors," J. Org. Chem (1999) 64:3714-3718.	<input type="checkbox"/>
15	Dugar et al., "Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 48461," Bioorganic & Medicinal Letters (1995) 5(24):2947-2952.	<input type="checkbox"/>
16	Mounsey et al., "Diet may slow progression of diabetic nephropathy," The Journal of Family Practice (2003) 52 (9):672-673.	<input type="checkbox"/>
17	Sobieszczyk et al., "Acute pulmonary embolism: don't ignore the platelet," Circulation (2002) 106(14):1748-1749.	<input type="checkbox"/>
18	van Heek et al., "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663," Br. J. Pharmacol (2000) 129(8):1748-1754.	<input type="checkbox"/>
19	Yang et al., "Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes," Circulation (2002) 105(16):1943-1948.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10596731
	Filing Date	2006-11-16
	First Named Inventor	Susanne Alenfalk
	Art Unit	1624
	Examiner Name	Mark L. Berch
	Attorney Docket Number	133087.10701 101340-1P US

	20	Zaks et al., "Enzymatic glucuronidation of a novel cholesterol absorption inhibitor, Sch 58235, Appl Biochem Biotechnol. (1998) 73(2-3):205-214.	<input type="checkbox"/>
	21	Clader "The discovery of ezetimibe: a view from outside the receptor," J Med Chem (2004) 47(1):1-9.	<input type="checkbox"/>
	22	Altmann et al., "Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption," Science(2004) 303:1201-1204.	<input type="checkbox"/>
	23	Notice of copending applications (2pp).	<input type="checkbox"/>
	24	Journal of the American College of Cardiology (2000) 35(1):252A.	<input type="checkbox"/>
	25	Kvaerno et al., "Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption," J Med Chem (2005) 48(19):6035-6053.	<input type="checkbox"/>
	26	Burnett "Beta-lactam cholesterol absorption inhibitors," Curr Med Chem (2004) 11:1873-1887.	<input type="checkbox"/>
	27	Seedorf et al., "Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages," Biochem Biophys Research Commun (2004) 320(4):1337-1341.	<input type="checkbox"/>
	28	Kvaerno et al., "An in vitro assay for evaluation of small-molecule inhibitors of cholesterol absorption," (2004) 43 (35):4653-4656.	<input type="checkbox"/>
	29	Clader "Ezetimibe and other azetidinone cholesterol absorption inhibitors," Curr Topics in Med Chem (2005) 5 (3):243-256.	<input type="checkbox"/>
	30	Garcia-Calvo et al., "The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)," PNAS (2005) 102(23):8132-8137.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10596731
	Filing Date	2006-11-16
	First Named Inventor	Susanne Alenfalk
	Art Unit	1624
	Examiner Name	Mark L. Berch
	Attorney Docket Number	133087.10701 101340-1P US

31	Ritter et al., "Heterocyclic ring scaffolds as small-molecule cholesterol absorption inhibitors," Org Biomol Chem (2005) 3:3514-3523.	<input type="checkbox"/>
----	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.